Copyright © 2008 Costas Giaginis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. Kahn, F. Mehraban, G. Ingle, et al., “Gene expression profiling in an in vitro model of angiogenesis,” American Journal of Pathology, vol. 156, no. 6, pp. 1887–1900, 2000.
2. N. M. Pandya, N. S. Dhalla, and D. D. Santani, “Angiogenesis—a new target for future therapy,” Vascular Pharmacology, vol. 44, no. 5, pp. 265–274, 2006. View at Publisher · View at Google Scholar · View at PubMed
3. G. E. Davis and D. R. Senger, “Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization,” Circulation Research, vol. 97, no. 11, pp. 1093–1107, 2005. View at Publisher · View at Google Scholar · View at PubMed
4. X. Dong, Z. C. Han, and R. Yang, “Angiogenesis and antiangiogenic therapy in hematologic malignancies,” Critical Reviews in Oncology/Hematology, vol. 62, no. 2, pp. 105–118, 2007. View at Publisher · View at Google Scholar · View at PubMed
5. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
6. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
7. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
8. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at PubMed
9. K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson, “Interaction of the peroxisome proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993. View at Publisher · View at Google Scholar
10. R. M. Tolón, A. I. Castillo, and A. Aranda, “Activation of the prolactin gene by peroxisome proliferator-activated receptor-$\alpha$ appears to be DNA binding-independent,” Journal of Biological Chemistry, vol. 273, no. 41, pp. 26652–26661, 1998. View at Publisher · View at Google Scholar
11. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-$\gamma$ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed
12. D. L. Feinstein, A. Spagnolo, C. Akar, et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?,” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005. View at Publisher · View at Google Scholar · View at PubMed
13. G. Pascual, A. L. Fong, S. Ogawa, et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-$\gamma$,” Nature, vol. 437, no. 7059, pp. 759–763, 2005. View at Publisher · View at Google Scholar · View at PubMed
14. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
15. F. J. Schopfer, Y. Lin, P. R. S. Baker, et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor $\gamma$ ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at PubMed
16. A. Jacob, R. Wu, M. Zhou, and P. Wang, “Mechanism of the anti-inflammatory effect of curcumin: PPAR-$\gamma$ activation,” PPAR Research, vol. 2007, Article ID 89369, 5 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
17. J. M. Lehmann, L. B. Moore, T.A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor $\gamma$ (PPAR$\gamma$),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
18. B. R. Henke, S. G. Blanchard, M. F. Brackeen, et al., “N-(2-benzoylphenyl)-L-tyrosine PPAR$\gamma$ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents,” Journal of Medicinal Chemistry, vol. 41, no. 25, pp. 5020–5036, 1998. View at Publisher · View at Google Scholar · View at PubMed
19. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors $\alpha$ and $\gamma$ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar
20. D. K. Wysowski, G. Armstrong, and L. Governale, “Rapid increase in the use of oral antidiabetic drugs in the United States, 1990–2001,” Diabetes Care, vol. 26, no. 6, pp. 1852–1855, 2003. View at Publisher · View at Google Scholar
21. S. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Peroxisome proliferator-activated receptor-$\gamma$ ligands as cell-cycle modulators,” Cancer Treatment Reviews, vol. 30, no. 6, pp. 545–554, 2004. View at Publisher · View at Google Scholar · View at PubMed
22. H. A. Pershadsingh, “Peroxisome proliferator-activated receptor-$\gamma$: therapeutic target for diseases beyond diabetes: quo vadis?,” Expert Opinion on Investigational Drugs, vol. 13, no. 3, pp. 215–228, 2004. View at Publisher · View at Google Scholar
23. C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis, “Peroxisome proliferator-activated receptor-$\gamma$ ligands as bone turnover modulators,” Expert Opinion on Investigational Drugs, vol. 16, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar · View at PubMed
24. C. Giaginis, S. Theocharis, and A. Tsantili-Kakoulidou, “A consideration of PPAR-$\gamma$ ligands with respect to lipophilicity: current trends and perspectives,” Expert Opinion on Investigational Drugs, vol. 16, no. 4, pp. 413–417, 2007. View at Publisher · View at Google Scholar · View at PubMed
25. C. Giaginis, S. Theocharis, and A. Tsantili-Kakoulidou, “Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-$\gamma$ activity,” Journal of Chromatography B, vol. 857, no. 2, pp. 181–187, 2007. View at Publisher · View at Google Scholar · View at PubMed
26. A. Margeli, G. Kouraklis, and S. Theocharis, “Peroxisome proliferator activated receptor-$\gamma$ (PPAR-$\gamma$) ligands and angiogenesis,” Angiogenesis, vol. 6, no. 3, pp. 165–169, 2003. View at Publisher · View at Google Scholar · View at PubMed
27. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, “PPAR$\gamma$ as a therapeutic target for tumor angiogenesis and metastasis,” Cancer Biology and Therapy, vol. 4, no. 7, pp. 687–693, 2005.
28. C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-$\gamma$ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007. View at Publisher · View at Google Scholar · View at PubMed
29. S. Han and J. Roman, “Peroxisome proliferator-activated receptor $\gamma$: a novel target for cancer therapeutics?,” Anti-Cancer Drugs, vol. 18, no. 3, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at PubMed
30. S. Theocharis, A. Margeli, and G. Kouraklis, “Peroxisome proliferator activated receptor-$\gamma$ ligands as potent antineoplastic agents,” Current Medicinal Chemistry, vol. 3, no. 3, pp. 239–251, 2003. View at Publisher · View at Google Scholar
31. R. W. C. Pang and R. T. P. Poon, “Clinical implications of angiogenesis in cancers,” Vascular Health and Risk Management, vol. 2, no. 2, pp. 97–108, 2006.
32. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at PubMed
33. M. E. Eichhorn, A. Kleespies, M. K. Angele, K.-W. Jauch, and C. J. Bruns, “Angiogenesis in cancer: molecular mechanisms, clinical impact,” Langenbeck's Archives of Surgery, vol. 392, no. 3, pp. 371–379, 2007. View at Publisher · View at Google Scholar · View at PubMed
34. J. Folkman and R. Kalluri, “Cancer without disease,” Nature, vol. 427, no. 6977, p. 787, 2004. View at Publisher · View at Google Scholar · View at PubMed
35. F. J. Giordano and R. S. Johnson, “Angiogenesis: the role of the microenvironment in flipping the switch,” Current Opinion in Genetics and Development, vol. 11, no. 1, pp. 35–40, 2001. View at Publisher · View at Google Scholar
36. M. M. Hickey and M. C. Simon, “Regulation of angiogenesis by hypoxia and hypoxia-inducible factors,” Current Topics in Developmental Biology, vol. 76, pp. 217–257, 2006. View at Publisher · View at Google Scholar · View at PubMed
37. D. Liao and R. S. Johnson, “Hypoxia: a ket regulator of angiogenesis in cancer,” Cancer Metastasis Reviews, vol. 26, no. 2, pp. 281–290, 2007. View at Publisher · View at Google Scholar · View at PubMed
38. R. L. Jensen, B. T. Ragel, K. Whang, and D. Gillespie, “Inhibition of hypoxia inducible factor-1$\alpha$ (HIF-1$\alpha$) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas,” Journal of Neuro-Oncology, vol. 78, no. 3, pp. 233–247, 2006. View at Publisher · View at Google Scholar · View at PubMed
39. A. W. Griffioen, “Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?,” Trends in Cardiovascular Medicine, vol. 17, no. 5, pp. 171–176, 2007. View at Publisher · View at Google Scholar · View at PubMed
40. A. Bikfalvi and R. Bicknell, “Recent advances in angiogenesis, anti-angiogenesis and vascular targeting,” Trends in Pharmacological Sciences, vol. 23, no. 12, pp. 576–582, 2002. View at Publisher · View at Google Scholar
41. G. Pagès and J. Pouysségur, “Transcriptional regulation of the vascular endothelial growth factor gene—a concert of activating factors,” Cardiovascular Research, vol. 65, no. 3, pp. 564–573, 2005. View at Publisher · View at Google Scholar · View at PubMed
42. S. P. Tabruyn and A. W. Griffioen, “Molecular pathways of angiogenic inhibition,” Biochemical Biophysical Research Communications, vol. 355, no. 1, pp. 1–5, 2007. View at Publisher · View at Google Scholar · View at PubMed
43. S. Ylä-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen, “Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine,” Journal of the American College of Cardiology, vol. 49, no. 10, pp. 1015–1026, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. A. Kiselyov, K. V. Balakin, and S. E. Tkachenko, “VEGF/VEGFR signalling as a target for inhibiting angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 1, pp. 83–107, 2007. View at Publisher · View at Google Scholar · View at PubMed
45. H. Zhong and J. P. Bowen, “Molecular design and clinical development of VEGFR kinase inhibitors,” Current Topics in Medicinal Chemistry, vol. 7, no. 14, pp. 1379–1393, 2007.
46. T. Kisseleva, L. Song, M. Vorontchikhina, N. Feirt, J. Kitajewski, and C. Schindler, “NF-$\kappa$B regulation of endothelial cell function during LPS-induced toxemia and cancer,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 2955–2963, 2006. View at Publisher · View at Google Scholar · View at PubMed
47. A. E. M. Dirkx, M. G. A. oude Egbrink, K. Castermans, et al., “Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors,” The FASEB Journal, vol. 20, no. 6, pp. 621–630, 2006. View at Publisher · View at Google Scholar · View at PubMed
48. X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor $\gamma$ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999. View at Publisher · View at Google Scholar
49. T. Murata, S. He, M. Hangai, et al., “Peroxisome proliferator-activated receptor-$\gamma$ ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000.
50. D. Bishop-Bailey and T. Hla, “Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy-${\Delta }^{12,14}$-prostaglandin ${\text{J}}_2$,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17042–17048, 1999. View at Publisher · View at Google Scholar
51. M. I. Freed, A. Allen, D. K. Jorkasky, and R. A. Dicicco, “Systematic exposure to rosiglitazone is unaltered by food,” European Journal of Clinical Pharmacology, vol. 55, no. 1, pp. 53–56, 1999. View at Publisher · View at Google Scholar
52. M. A. Sarayba, L. Li, T. Tungsiripat, et al., “Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-$\gamma$ ligand,” Experimental Eye Research, vol. 80, no. 3, pp. 435–442, 2005. View at Publisher · View at Google Scholar · View at PubMed
53. W. H.-H. Sheu, H.-C. Ou, F.-P. Chou, T.-M. Lin, and C.-H. Yang, “Rosiglitazone inhibits endothelial proliferation and angiogenesis,” Life Sciences, vol. 78, no. 13, pp. 1520–1528, 2006. View at Publisher · View at Google Scholar · View at PubMed
54. K. Y. Kim and H. G. Cheon, “Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor $\gamma$-activated maxi-K channel opening in human umbilical vein endothelial cells,” Journal of Biological Chemistry, vol. 281, no. 19, pp. 13503–13512, 2006. View at Publisher · View at Google Scholar · View at PubMed
55. D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo, “Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) $\gamma$-dependent and PPAR$\gamma$-independent signaling pathways,” Journal of Biological Chemistry, vol. 279, no. 4, pp. 2499–2506, 2004. View at Publisher · View at Google Scholar · View at PubMed
56. T.-C. Ho, S.-L. Chen, Y.-C. Yang, C.-L. Liao, H.-C. Cheng, and Y.-P. Tsao, “PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells,” Cardiovascular Research, vol. 76, no. 2, pp. 213–223, 2007. View at Publisher · View at Google Scholar · View at PubMed
57. D. Panigrahy, S. Singer, L. Q. Shen, et al., “PPAR$\gamma$ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar
58. B. Farrow, K. L. O'Connor, K. Hashimoto, T. Iwamura, and B. M. Evers, “Selective activation of PPAR$\gamma$ inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator,” Surgery, vol. 134, no. 2, pp. 206–212, 2003. View at Publisher · View at Google Scholar · View at PubMed
59. H. Liu, C. Zang, M. H. Fenner, K. Possinger, and E. Elstner, “PPAR$\gamma$ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro,” Breast Cancer Research and Treatment, vol. 79, no. 1, pp. 63–74, 2003. View at Publisher · View at Google Scholar
60. L. L. H. Peeters, J.-L. Vigne, M. K. Tee, D. Zhao, L. L. Waite, and R. N. Taylor, “PPAR$\gamma$ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis,” Angiogenesis, vol. 8, no. 4, pp. 373–379, 2006. View at Publisher · View at Google Scholar · View at PubMed
61. N. Hayashi, S. Nakamori, N. Hiraoka, et al., “Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma,” International Journal of Oncology, vol. 24, no. 1, pp. 89–95, 2004.
62. H. Huang, S. C. Campbell, D. F. Bedford, et al., “Peroxisome proliferator-activated receptor $\gamma$ ligands improve the antitumor efficacy of thrombospondin peptide ABT510,” Molecular Cancer Research, vol. 2, no. 10, pp. 541–550, 2004.
63. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford, “PPAR-$\gamma$ activation inhibits angiogenesis by blocking $\text{ELR}+\text{CXC}$ chemokine production in non-small cell lung cancer,” Neoplasia, vol. 7, no. 3, pp. 294–301, 2005. View at Publisher · View at Google Scholar · View at PubMed
64. S. Hazra and S. M. Dubinett, “Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 77, no. 1, pp. 51–58, 2007. View at Publisher · View at Google Scholar · View at PubMed
65. B. Xin, Y. Yokoyama, T. Shigeto, M. Futagami, and H. Mizunuma, “Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers,” Cancer, vol. 110, no. 4, pp. 791–800, 2007. View at Publisher · View at Google Scholar · View at PubMed
66. J. Yuan, A. Takahashi, N. Masumori, et al., “Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma,” Urology, vol. 65, no. 3, pp. 594–599, 2005. View at Publisher · View at Google Scholar · View at PubMed
67. Y.-G. Fu, J. J. Y. Sung, K.-C. Wu, et al., “Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin ${\text{J}}_2$ through the downregulation of angiopoietin-1,” Cancer Letters, vol. 243, no. 2, pp. 246–254, 2006. View at Publisher · View at Google Scholar · View at PubMed
68. P. Haslmayer, T. Thalhammer, W. Jäger, et al., “The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-${\Delta }^{12,14}$-prostaglandin ${\text{J}}_2$ induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637,” International Journal of Oncology, vol. 21, no. 4, pp. 915–920, 2002.
69. E.-H. Kim, H.-K. Na, and Y.-J. Surh, “Upregulation of VEGF by 15-deoxy-${\Delta }^{12,14}$-prostaglandin ${\text{J}}_2$ via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells,” Annals of the New York Academy of Sciences, vol. 1090, pp. 375–384, 2006. View at Publisher · View at Google Scholar · View at PubMed
70. K. Hashimoto, R. T. Ethridge, and B. M. Evers, “Peroxisome proliferator-activated receptor $\gamma$ ligand inhibits cell growth and invasion of human pancreatic cancer cells,” International Journal of Gastrointestinal Cancer, vol. 32, no. 1, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at PubMed
71. J. A. Copland, L. A. Marlow, S. Kurakata, et al., “Novel high-affinity PPAR$\gamma$ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via ${\text{p21}}^{\text{WAF1/CIP1}}$,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006. View at Publisher · View at Google Scholar · View at PubMed
72. G. Eibl, Y. Takata, L. G. Boros, et al., “Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor,” Cancer Research, vol. 65, no. 3, pp. 982–990, 2005.
73. Y. Bren-Mattison, V. Van Putten, D. Chan, R. Winn, M. W. Geraci, and R. A. Nemenoff, “Peroxisome proliferator-activated receptor-$\gamma$ (PPAR$\gamma$) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC),” Oncogene, vol. 24, no. 8, pp. 1412–1422, 2005. View at Publisher · View at Google Scholar · View at PubMed
74. N. Ruiz-Velasco, A. Domínguez, and M. A. Vega, “Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-$\gamma$ ligands Putative contribution of Rho GTPases in statin-induced CD36 expression,” Biochemical Pharmacology, vol. 67, no. 2, pp. 303–313, 2004. View at Publisher · View at Google Scholar
75. M. Febbraio, D. P. Hajjar, and R. L. Silverstein, “CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism,” Journal of Clinical Investigation, vol. 108, no. 6, pp. 785–791, 2001. View at Publisher · View at Google Scholar
76. Y. Barak, M. C. Nelson, E. S. Ong, et al., “PPAR$\gamma$ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
77. S. E. Crawford, C. Qi, P. Misra, et al., “Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors,” Journal of Biological Chemistry, vol. 277, no. 5, pp. 3585–3592, 2002. View at Publisher · View at Google Scholar · View at PubMed
78. M. Artwohl, C. Fürnsinn, W. Waldhäusl, et al., “Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPAR$\gamma$-independent mechanism,” Diabetologia, vol. 48, no. 3, pp. 586–594, 2005. View at Publisher · View at Google Scholar · View at PubMed
79. Y. Sassa, Y. Hata, L. P. Aiello, Y. Taniguchi, K. Kohno, and T. Ishibashi, “Bifunctional properties of peroxisome proliferator-activated receptor $\gamma$1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3,” Diabetes, vol. 53, no. 5, pp. 1222–1229, 2004. View at Publisher · View at Google Scholar
80. G. Frühbeck, “Intracellular signalling pathways activated by leptin,” Biochemical Journal, vol. 393, no. 1, pp. 7–20, 2006. View at Publisher · View at Google Scholar · View at PubMed
81. M. R. Sierra-Honigmann, A. K. Nath, C. Murakami, et al., “Biological action of leptin as an angiogenic factor,” Science, vol. 281, no. 5383, pp. 1683–1686, 1998. View at Publisher · View at Google Scholar
82. H. Qian, G. J. Hausman, M. M. Compton, M. J. Azain, D. L. Hartzell, and C. A. Baile, “Leptin regulation of peroxisome proliferator-activated receptor-$\gamma$, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues,” Biochemical and Biophysical Research Communications, vol. 246, no. 3, pp. 660–667, 1998. View at Publisher · View at Google Scholar · View at PubMed
83. J. Rieusset, J. Auwerx, and H. Vidal, “Regulation of gene expression by activation of the peroxisome proliferator-activated receptor $\gamma$ with rosiglitazone (BRL 49653) in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 265–271, 1999. View at Publisher · View at Google Scholar · View at PubMed
84. S. Goetze, A. Bungenstock, C. Czupalla, et al., “Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR$\gamma$-ligands,” Hypertension, vol. 40, no. 5, pp. 748–754, 2002. View at Publisher · View at Google Scholar
85. T. Vogt, C. Hafner, K. Bross, et al., “Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors,” Cancer, vol. 98, no. 10, pp. 2251–2256, 2003. View at Publisher · View at Google Scholar · View at PubMed
86. B. Coras, C. Hafner, A. Reichle, et al., “Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in a patient with endemic Kaposi sarcoma,” Archives of Dermatology, vol. 140, no. 12, pp. 1504–1507, 2004. View at Publisher · View at Google Scholar · View at PubMed
87. A. S. Boyd, “Thiazolidinediones in dermatology,” International Journal of Dermatology, vol. 46, no. 6, pp. 557–563, 2007. View at Publisher · View at Google Scholar · View at PubMed
88. A. Jozkowicz, J. Dulak, E. Piatkowska, W. Placha, and A. Dembinska-Kiec, “Ligands of peroxisome proliferator-activated receptor-$\gamma$ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages,” Acta Biochimica Polonica, vol. 47, no. 4, pp. 1147–1157, 2000.
89. K. Yamakawa, M. Hosoi, H. Koyama, et al., “Peroxisome proliferator-activated receptor-$\gamma$ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 571–574, 2000. View at Publisher · View at Google Scholar · View at PubMed
90. V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa, “PPAR-$\gamma$ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts,” Cardiovascular Research, vol. 74, no. 1, pp. 140–150, 2007. View at Publisher · View at Google Scholar · View at PubMed
91. K. Chu, S.-T. Lee, J.-S. Koo, et al., “Peroxisome proliferator-activated receptor-$\gamma$-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia,” Brain Research, vol. 1093, no. 1, pp. 208–218, 2006. View at Publisher · View at Google Scholar · View at PubMed
92. F. Pistrosch, K. Herbrig, U. Oelschlaegel, et al., “PPAR$\gamma$-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells,” Atherosclerosis, vol. 183, no. 1, pp. 163–167, 2005. View at Publisher · View at Google Scholar · View at PubMed
93. C.-H. Wang, M.-K. Ting, S. Verma, et al., “Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus,” American Heart Journal, vol. 152, no. 6, pp. 1051.e1–1051.e8, 2006. View at Publisher · View at Google Scholar · View at PubMed
94. C. Gensch, Y. P. Clever, C. Werner, M. Hanhoun, M. Böhm, and U. Laufs, “The PPAR-$\gamma$ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells,” Atherosclerosis, vol. 192, no. 1, pp. 67–74, 2007. View at Publisher · View at Google Scholar · View at PubMed
95. C. Werner, C. H. Kamani, C. Gensch, M. Böhm, and U. Laufs, “The peroxisome proliferator-activated receptor-$\gamma$ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance,” Diabetes, vol. 56, no. 10, pp. 2609–2615, 2007. View at Publisher · View at Google Scholar · View at PubMed
96. C. E. Clay, A. M. Namen, G. Atsumi, et al., “Magnitude of peroxisome proliferator-activated receptor-$\gamma$ activation is associated with important and seemingly opposite biological responses in breast cancer cells,” Journal of Investigative Medicine, vol. 49, no. 5, pp. 413–420, 2001. View at Publisher · View at Google Scholar
97. Y. Ye, S. P. Nishi, S. Manickavasagam, et al., “Activation of peroxisome proliferator-activated receptor-$\gamma$ (PPAR-$\gamma$) by atorvastatin is mediated by 15-deoxy-${\Delta }^{12,14}$-${\text{PGJ}}_2$,” Prostaglandins and Other Lipid Mediators, vol. 84, no. 1-2, pp. 43–53, 2007. View at Publisher · View at Google Scholar · View at PubMed
98. P. R. S. Baker, Y. Lin, F. J. Schopfer, et al., “Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42464–42475, 2005. View at Publisher · View at Google Scholar · View at PubMed
99. S. Fauconnet, I. Lascombe, E. Chabannes, et al., “Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells,” Journal of Biological Chemistry, vol. 277, no. 26, pp. 23534–23543, 2002. View at Publisher · View at Google Scholar · View at PubMed
100. L. Possati, R. Rocchetti, S. Talevi, et al., “The role of peroxisome proliferator-activated receptor $\gamma$ in bladder cancer in relation to angiogenesis and progression,” General Pharmacology, vol. 35, no. 5, pp. 269–275, 2000. View at Publisher · View at Google Scholar
101. T. Nijsten, E. Geluyckens, C. Colpaert, and J. Lambert, “Peroxisome proliterator-activated receptors in squamous cell carcinoma and its precursors,” Journal of Cutaneous Pathology, vol. 32, no. 5, pp. 340–347, 2005. View at Publisher · View at Google Scholar · View at PubMed
102. A. Jones, C. Fujiyama, C. Blanche, et al., “Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1$\alpha$ and hypoxia-inducible factor-2$\alpha$ in human bladder tumors and cell lines,” Clinical Cancer Research, vol. 7, no. 5, pp. 1263–1272, 2001.
103. R. E. Nisbet, R. L. Sutliff, and C. M. Hart, “The role of peroxisome proliferator-activated receptors in pulmonary vascular disease,” PPAR Research, vol. 2007, Article ID 18797, 10 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
104. J. T. Crossno, Jr., C. V. Garat, J. E. B. Reusch, et al., “Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 292, no. 4, pp. L885–L897, 2007. View at Publisher · View at Google Scholar · View at PubMed
105. M. P. Diamond and G. Saed, “Modulation of the expression of peroxisome proliferators-activated receptors in human fibroblasts,” Fertility and Sterility, vol. 87, no. 3, pp. 706–709, 2007. View at Publisher · View at Google Scholar · View at PubMed
106. X. Li, H. Kimura, K. Hirota, et al., “Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-$\gamma$ in human proximal renal tubular cells,” Nephrology Dialysis Transplantation, vol. 22, no. 4, pp. 1041–1051, 2007. View at Publisher · View at Google Scholar · View at PubMed
107. E.-H. Kim and Y.-J. Surh, “15-deoxy-${\Delta }^{12,14}$-prostaglandin ${\text{J}}_2$ as a potential endogenous regulator of redox-sensitive transcription factors,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1516–1528, 2006. View at Publisher · View at Google Scholar · View at PubMed